Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.65 USD
Change Today -0.01 / -0.38%
Volume 1.6M
BLRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Tel Aviv
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

biolinerx ltd-spons adr (BLRX) Snapshot

Open
$2.72
Previous Close
$2.66
Day High
$2.80
Day Low
$2.55
52 Week High
03/5/15 - $3.28
52 Week Low
11/28/14 - $1.20
Market Cap
143.5M
Average Volume 10 Days
3.0M
EPS TTM
--
Shares Outstanding
54.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOLINERX LTD-SPONS ADR (BLRX)

biolinerx ltd-spons adr (BLRX) Related Businessweek News

No Related Businessweek News Found

biolinerx ltd-spons adr (BLRX) Details

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company’s development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a novel polymer solution for use in the prevention of ventricular remodeling following an acute myocardial infarction; BL-8040, a novel peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a novel polymer for the treatment of celiac disease; BL-5010, a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the hepatitis C virus and other viral indications. It also has four therapeutic candidates in the preclinical stages of development, including BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies and asthma; BL-9020 for the treatment of type 1 diabetes; and BL-1110 for the treatment of neuropathic pain and scleroderma. The company has strategic collaboration with Novartis Pharma AG for the co-development of drug candidates. BioLineRx Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

46 Employees
Last Reported Date: 03/23/15
Founded in 2003

biolinerx ltd-spons adr (BLRX) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $366.0K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $269.0K
Vice President of Business Development
Total Annual Compensation: $241.0K
Vice President of Medical Affairs
Total Annual Compensation: $185.0K
Chief Scientific Officer
Total Annual Compensation: $215.0K
Compensation as of Fiscal Year 2014.

biolinerx ltd-spons adr (BLRX) Key Developments

BioLineRx, Ltd. Presents Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment at European Hematology Association Conference

BioLineRx Ltd. announced the presentation of positive safety and efficacy results for its oncology candidate, BL-8040, as a novel approach for the collection of stem cells from the peripheral blood circulation. Treatment with BL-8040 as a single agent was found safe and well tolerated at all doses, and resulted in efficient stem-cell mobilization and collection in all study participants. Furthermore, the results support BL-8040 as a one-day, single-dose collection regimen, which is a significant improvement compared to the current standard of care. The full Phase 1 data set was presented on June 14, 2015 in an oral presentation at the 20th Annual Congress of the European Hematology Association (EHA) in Vienna, Austria. These results support a novel approach to stem-cell collection for transplantation purposes in patients with hematological malignancies or other indications. Importantly, the collection of CD34+ cells was accompanied by mobilization and collection of colony-forming cells, as well as T, B and NK cells. The collected human graft was further assessed for its viability and quality in vitro and in vivo. The cells collected from the subjects treated with BL-8040 showed engraftment in irradiated mice, followed by a rapid reconstitution of normal hematopoiesis. The Phase 1 clinical trial was performed on healthy volunteers and consisted of two parts. The first part of the study was a randomized, double-blind, placebo-controlled, dose-escalation study in three cohorts of eight participants each, with each participant receiving two consecutive injections of BL-8040. Results show that BL-8040 is safe and well tolerated up to a dose of 1 mg/kg, and that dramatic mobilization of hematopoietic stem and progenitor cells (HSPCs) was observed across all doses tested. The robust mobilization supports the further use of a single injection of BL-8040 for HSPC collection. In the second part of the Phase 1 study, eight healthy participants received a single injection of BL-8040 at the dose of 1 mg/kg, and four hours later underwent a single, standard leukapheresis procedure. Robust and rapid stem-cell mobilization was evident in all treated participants, supporting a novel approach to stem-cell collection. The median level of collected stem cells was higher than 11 x 106 cells per kg, and the level of HPSCs in the peripheral blood circulation 24 hours after injection of BL-8040 enabled an additional apheresis on Day 2, if needed. These data support the use of BL-8040 as a single-agent, single-injection, one-day regimen for the collection of stem cells.

BioLineRx, Ltd. Announces Peer-Reviewed Publication of Phase 1/2 Trial Results for Novel Treatment for Non-Surgical Removal of Skin Lesions

BioLineRx Ltd. announced the publication of positive results from the Phase 1/2 clinical trial of BL-5010, a novel formulation for the non-surgical removal of skin lesions. The publication details the results, which were previously disclosed by BioLineRx in December 2010, of an open-label, single-arm trial conducted in 60 patients with seborrheic keratosis in Germany and the Netherlands. The objectives of the study were to determine the safety and efficacy of BL-5010 in completely removing the lesion and to assess the cosmetic outcome of the novel treatment. The study also aimed at evaluating BL-5010’s feasibility in preserving the lesions for subsequent histological examination. The results of the trial show that for nearly all patients (96.7%), the lesion fell off within 30 days of a single application of BL-5010. Furthermore, the results show that BL-5010 has a good safety profile, as no persistent irreversible adverse effects were observed at the treated site. Histological examination of the lesions showed that BL-5010 enables preservation of the histological structure of the treated lesion. BL-5010 is a novel product for the non-surgical removal of benign skin lesions. It offers an alternative to painful, invasive and expensive removal treatments including cryotherapy, laser treatment and surgery. Because the treatment is non-invasive, it poses minimal infection risk and eliminates the need for anesthesia or bandaging. The product has completed a phase 1/2 pilot clinical study for the removal of seborrheic keratosis, which showed excellent efficacy and cosmetic results, and has received confirmation in Europe for the regulatory pathway classification as a medical device Class 2a.

BioLineRx, Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

BioLineRx, Ltd. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015.  For the quarter, the company reported operating loss of USD 4,327,000 against USD 4,076,000 a year ago. Net loss was USD 4,311,000 or USD 0.008 per basic and diluted share against USD 2,115,000 or USD 0.010 per diluted share a year ago. Net cash used in operating activities was USD 3,468,000 against USD 3,391,000 a year ago. Purchase of property and equipment was USD 149,000 against USD 47,000 a year ago. The USD 0.1 million increase in net cash used in operating activities during the three-month period in 2015, compared to the three-month period in 2014, was primarily the result of increased research and development spending, partially offset by an increase in trade payables and accruals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLRX:US $2.65 USD -0.01

BLRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLRX.
View Industry Companies
 

Industry Analysis

BLRX

Industry Average

Valuation BLRX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLINERX LTD-SPONS ADR, please visit www.biolinerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.